Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Severe combined immunodeficiencies.

A Fischer1

  • 1INSERM U 132, Hôpital des Enfants-Malades, Paris, France.

Immunodeficiency Reviews
|January 1, 1992
PubMed
Summary
This summary is machine-generated.

Severe combined immunodeficiencies (SCID) are complex immune system disorders. Advances in bone marrow transplantation and gene therapy offer promising treatments for SCID patients.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

CD2-induced apoptosis in activated human peripheral T cells: a Fas-independent pathway that requires early protein tyrosine phosphorylation.

Journal of immunology (Baltimore, Md. : 1950)·1996
Same author

Lack of detectable defect in DNA double-strand break repair and DNA-dependent protein kinase activity in radiosensitive human severe combined immunodeficiency fibroblasts.

European journal of immunology·1996
Same author

gamma-c gene transfer into SCID X1 patients' B-cell lines restores normal high-affinity interleukin-2 receptor expression and function.

Blood·1996
Same author

Clinical, hematologic, and biochemical features of a syndrome in Bernese mountain dogs characterized by hepatocerebellar degeneration.

Journal of the American Veterinary Medical Association·1996
Same author

A phase II trial of partially incompatible bone marrow transplantation for high-risk acute lymphoblastic leukaemia in children: prevention of graft rejection with anti-LFA-1 and anti-CD2 antibodies. Société Française de Greffe de Moelle Osseuse.

British journal of haematology·1996
Same author

Radiommunological measurement of leptin in plasma of obese and diabetic human subjects.

Endocrinology·1996
Same journal

Molecular basis of the autosomal recessive forms of chronic granulomatous disease.

Immunodeficiency reviews·1992
Same journal

Inherited deficiencies of the terminal components of human complement.

Immunodeficiency reviews·1992
Same journal

Immunodeficiency with hyper-IgM (HIM).

Immunodeficiency reviews·1992
Same journal

Nonhuman primate models for HIV vaccine development.

Immunodeficiency reviews·1992
Same journal

Primary immunodeficiency diseases. Report of a WHO scientific group.

Immunodeficiency reviews·1992
Same journal

Gene therapy for primary immunodeficiency disease.

Immunodeficiency reviews·1992
See all related articles

Area of Science:

  • Immunology
  • Genetics
  • Pediatrics

Background:

  • Severe combined immunodeficiencies (SCID) encompass a diverse group of disorders marked by severe defects in T cell development or function.
  • While the molecular basis for some SCID cases, like purine metabolism enzyme deficiencies, is understood, others involve complex genetic and cellular mechanisms.
  • Progress has been made in identifying genes responsible for SCID, such as X-linked SCID, and elucidating underlying mechanisms like abnormal gene rearrangements and signal transduction defects.

Purpose of the Study:

  • To review the current understanding of the heterogeneous nature of severe combined immunodeficiencies (SCID).
  • To summarize recent advancements in the diagnosis and therapeutic strategies for SCID.
  • To highlight the future prospects of gene therapy for SCID.

Related Experiment Videos

Main Methods:

  • Literature review of genetic defects, immunological mechanisms, and therapeutic outcomes in SCID.
  • Analysis of advancements in bone marrow transplantation (BMT) for SCID treatment.
  • Evaluation of emerging therapies, including enzyme replacement and gene therapy.

Main Results:

  • Bone marrow transplantation, using HLA-identical or non-identical donors, has achieved a cure rate of at least 75% for SCID patients.
  • Enzyme replacement therapy with polyethylene glycol-adenosine deaminase (PEG-ADA) is an alternative treatment for adenosine deaminase deficiency SCID.
  • Gene therapy holds significant promise as a future treatment option for SCID and related disorders.

Conclusions:

  • SCID is a complex group of diseases with diverse molecular etiologies.
  • Significant therapeutic progress has been made, with BMT being a highly effective treatment.
  • Gene therapy represents a promising frontier for the future management of SCID.